Phenylephrine drops - Paragon Bioteck

Drug Profile

Phenylephrine drops - Paragon Bioteck

Alternative Names: Phenylephrine hydrochloride - Paragon Bioteck; R-phenylephrine hydrochloride

Latest Information Update: 27 Nov 2016

Price : $50

At a glance

  • Originator Paragon Bioteck
  • Developer Bausch & Lomb; Paragon Bioteck
  • Class Antihypotensives; Decongestants; Ethanolamines; Mydriatics; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Miosis

Most Recent Events

  • 21 Nov 2016 USPTO hands out ruling affirming claims made by Paragon Bioteck in regards to the patent for its phenylephrine hydrochloride formulation
  • 01 Apr 2014 Launched for Miosis (prevention) in USA (Ophthalmic)
  • 05 Aug 2013 Bausch & Lomb has been acquired by Valeant Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top